Case Studies and Clinical Trials

Case studies can be defined as the intensive study of any particular individual, community or group in which the researcher analyses several variables to derive a conclusion. Case studies are the best way to study any particular field by getting a practical overview of the respective case. Case studies do not have any set of procedures to follow. It helps another person to gain practical knowledge and help them to enhance or improve their own ability to perform the same task with better precision.
Clinical trials are the study that concludes how safe the treatments, tests, and medicine are.

Sub-tracks: 

• Neurology Case Studies
• Neurosurgery Case Studies
• Parkinson's Case Studies
• Epilepsy Case Studies
• Alzheimer's Case Studies
• Movement Disorder Case Studies
• Neurology Clinical Trials
• Neurosurgery Clinical Trials
• Parkinson's Clinical Trials
• Epilepsy Clinical Trials
• Alzheimer's Clinical Trials
• Movement Disorder Clinical Trials

Market Analysis: The global market for neurology clinical trials is expected to reach USD 7.4 billion by 2028, according to a new study by Grand View Research, Inc. The market is expected to increase at a 5.5 percent CAGR between 2021 and 2028. This is due to big pharma companies conducting new neurology trials, increased government financing from the National Institute of Neurological Disorders and Stroke (NINDS), and strict regulatory standards for clinical trials. The global market for neurology clinical trials is expected to reach USD 7.4 billion by 2028. From 2021 to 2028, the market is estimated to grow at a CAGR of 5.5 percent. Neuroscience continues to attract a good amount of early funding. In 2018, it attracted USD 1.5 billion in venture capital funding, second only to cancer, indicating that investors believe a huge pharma acquisition will pay off soon. Early detection of diseases is attracting investment and driving dealmaking in the complex neuroscience sector, particularly for pain and Alzheimer's disease, as the industry attempts to move past the many late-stage clinical failures of recent years.